Predicting Human Clinical Outcomes Using Mouse Multi-Organ Transcriptome
Satoshi Kozawa,
Fumihiko Sagawa,
Satsuki Endo,
Glicia Maria De Almeida,
Yuto Mitsuishi,
Thomas N. Sato
Affiliations
Satoshi Kozawa
Karydo TherapeutiX, Inc., Kyoto, Japan; ERATO Sato Live Bio-Forecasting Project, Kyoto, Japan; The Thomas N. Sato BioMEC-X Laboratories, Advanced Telecommunications Research Institute International, 2-2-2 Hikaridai, Seika-cho, Soraku-gun, Kyoto 619-0288, Japan
Fumihiko Sagawa
Karydo TherapeutiX, Inc., Kyoto, Japan; ERATO Sato Live Bio-Forecasting Project, Kyoto, Japan; The Thomas N. Sato BioMEC-X Laboratories, Advanced Telecommunications Research Institute International, 2-2-2 Hikaridai, Seika-cho, Soraku-gun, Kyoto 619-0288, Japan
Satsuki Endo
Karydo TherapeutiX, Inc., Kyoto, Japan; ERATO Sato Live Bio-Forecasting Project, Kyoto, Japan; The Thomas N. Sato BioMEC-X Laboratories, Advanced Telecommunications Research Institute International, 2-2-2 Hikaridai, Seika-cho, Soraku-gun, Kyoto 619-0288, Japan
Glicia Maria De Almeida
Karydo TherapeutiX, Inc., Kyoto, Japan
Yuto Mitsuishi
Karydo TherapeutiX, Inc., Kyoto, Japan
Thomas N. Sato
Karydo TherapeutiX, Inc., Kyoto, Japan; ERATO Sato Live Bio-Forecasting Project, Kyoto, Japan; The Thomas N. Sato BioMEC-X Laboratories, Advanced Telecommunications Research Institute International, 2-2-2 Hikaridai, Seika-cho, Soraku-gun, Kyoto 619-0288, Japan; Biomedical Engineering, Cornell University, Ithaca, NY, USA; Centenary Institute, Sydney, Australia; V-iClinix Laboratory, Nara Medical University, Nara, Japan; Corresponding author
Summary: Approximately 90% of pre-clinically validated drugs fail in clinical trials owing to unanticipated clinical outcomes, costing over several hundred million US dollars per drug. Despite such critical importance, translating pre-clinical data to clinical outcomes remain a major challenge. Herein, we designed a modality-independent and unbiased approach to predict clinical outcomes of drugs. The approach exploits their multi-organ transcriptome patterns induced in mice and a unique mouse-transcriptome database “humanized” by machine learning algorithms and human clinical outcome datasets. The cross-validation with small-molecule, antibody, and peptide drugs shows effective and efficient identification of the previously known outcomes of 5,519 adverse events and 11,312 therapeutic indications. In addition, the approach is adaptable to deducing potential molecular mechanisms underlying these outcomes. Furthermore, the approach identifies previously unsuspected repositioning targets. These results, together with the fact that it requires no prior structural or mechanistic information of drugs, illustrate its versatile applications to drug development process. : Biological Sciences; Bioinformatics; Biocomputational Method; Computational Bioinformatics; Pharmacoinformatics Subject Areas: Biological Sciences, Bioinformatics, Biocomputational Method, Computational Bioinformatics, Pharmacoinformatics